HK1030362A1 - Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization - Google Patents

Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization

Info

Publication number
HK1030362A1
HK1030362A1 HK01101081A HK01101081A HK1030362A1 HK 1030362 A1 HK1030362 A1 HK 1030362A1 HK 01101081 A HK01101081 A HK 01101081A HK 01101081 A HK01101081 A HK 01101081A HK 1030362 A1 HK1030362 A1 HK 1030362A1
Authority
HK
Hong Kong
Prior art keywords
dimethylaminopropylidene
dihydrodibenz
oxepin
medicament
prevention
Prior art date
Application number
HK01101081A
Other languages
English (en)
Inventor
John M Yanni
Daniel A Gamache
Lori K Weimer
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of HK1030362A1 publication Critical patent/HK1030362A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01101081A 1998-07-14 2001-02-14 Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization HK1030362A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9276298P 1998-07-14 1998-07-14
PCT/US1999/013275 WO2000003705A1 (en) 1998-07-14 1999-06-15 Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization

Publications (1)

Publication Number Publication Date
HK1030362A1 true HK1030362A1 (en) 2001-05-04

Family

ID=22235027

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101081A HK1030362A1 (en) 1998-07-14 2001-02-14 Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization

Country Status (18)

Country Link
EP (1) EP1037627B1 (el)
JP (1) JP2002520355A (el)
KR (1) KR100598723B1 (el)
CN (1) CN1114401C (el)
AR (1) AR019916A1 (el)
AT (1) ATE203668T1 (el)
AU (1) AU742237B2 (el)
BR (1) BR9906772A (el)
CA (1) CA2306393C (el)
DE (1) DE69900207T2 (el)
DK (1) DK1037627T3 (el)
ES (1) ES2159209T3 (el)
GR (1) GR3036422T3 (el)
HK (1) HK1030362A1 (el)
PT (1) PT1037627E (el)
TW (1) TW561046B (el)
WO (1) WO2000003705A1 (el)
ZA (1) ZA200001593B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420399B1 (en) 1999-06-18 2002-07-16 Alcon Manufacturing, Ltd. Topical ophthalmic mast cell stabilizers for treating allergic eye disease
US20020077358A1 (en) * 2000-10-23 2002-06-20 Alcon Universal Ltd. Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery
WO2002095704A1 (en) * 2001-05-21 2002-11-28 Alcon, Inc. Use of nf-kappa-b inhibitors to treat dry eye disorders
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
ES2278049T3 (es) 2001-05-21 2007-08-01 Alcon, Inc. Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US6825232B2 (en) 2002-06-14 2004-11-30 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
CN1684701B (zh) 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
KR20050057175A (ko) * 2002-09-20 2005-06-16 알콘, 인코퍼레이티드 안구건조증 치료용 사이토카인 합성 저해제의 용도
WO2004093878A1 (en) * 2003-04-16 2004-11-04 Alcon, Inc. Use of fused pyridazine derivatives for treating dry eye disorders
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
JP2008504938A (ja) 2004-07-02 2008-02-21 レイザー，エリオット 治療媒体送出装置およびその送出装置を用いて治療媒体を眼に送り出す方法
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
CA2960117C (en) 2005-05-17 2018-01-30 Sarcode Bioscience Inc. Lfa-1 antagonists for the treatment of eye disorders
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
EP2010143B1 (en) 2006-03-17 2015-08-12 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
BRPI0709672B8 (pt) 2006-03-31 2021-06-22 3088922 Inc implante ocular insersível em um lúmen ocular e método de distribuição de um agente terapêutico a um olho
KR20100067099A (ko) 2007-09-07 2010-06-18 큐엘티 플러그 딜리버리, 인코포레이티드 눈물 임플랜트 검출
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
AU2010314956A1 (en) 2009-11-06 2012-04-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CA3032790A1 (en) 2016-06-20 2017-12-28 Novartis Ag Methods of treating dry eye disease using tnf.alpha. antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
JPH02138215A (ja) * 1988-08-05 1990-05-28 Dai Ichi Seiyaku Co Ltd 抗アレルギー・抗炎症剤
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
JP3453152B2 (ja) * 1992-04-06 2003-10-06 格 冨山 抗炎症点眼剤
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
ATE241359T1 (de) * 1993-03-26 2003-06-15 Beth Israel Hospital Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
FR2711990B1 (fr) * 1993-11-05 1995-12-08 Exsymol Sa Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires.
JP2852607B2 (ja) * 1994-06-10 1999-02-03 雪印乳業株式会社 ドライアイ治療剤
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
JPH1067684A (ja) * 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
CA2272073A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye

Also Published As

Publication number Publication date
KR100598723B1 (ko) 2006-07-11
DE69900207T2 (de) 2001-11-22
CA2306393C (en) 2008-12-23
AR019916A1 (es) 2002-03-27
WO2000003705A1 (en) 2000-01-27
BR9906772A (pt) 2000-09-26
TW561046B (en) 2003-11-11
KR20010024508A (ko) 2001-03-26
JP2002520355A (ja) 2002-07-09
ZA200001593B (en) 2000-10-25
PT1037627E (pt) 2001-11-30
CN1275078A (zh) 2000-11-29
AU742237B2 (en) 2001-12-20
CN1114401C (zh) 2003-07-16
ES2159209T3 (es) 2001-09-16
DE69900207D1 (de) 2001-09-06
CA2306393A1 (en) 2000-01-27
AU4563499A (en) 2000-02-07
EP1037627B1 (en) 2001-08-01
DK1037627T3 (da) 2001-10-01
ATE203668T1 (de) 2001-08-15
GR3036422T3 (en) 2001-11-30
EP1037627A1 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
HK1030362A1 (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
HK1085647A1 (en) Benzo [d]azepine derivatives for the treatment of neurological disorders
MY116651A (en) Topical ophthalmic formulations for treating allergic eye diseases
HUP0000576A3 (en) Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts
EP1600167A3 (en) A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders
IL179017A0 (en) Solid oral dosage form comprising valsartan
PL352229A1 (en) Prosthesis of sclera for treatment of presbyopia and other sight disorders
HK1023293A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
EP1440689A3 (en) Treatment of neurotic disorders
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
IL145269A0 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
AU5912900A (en) Quinuclidine derivatives for treatment of neurological disorders
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
CA2260863A1 (en) Treatment of psychotic disorders
CA2388728A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
IL155431A0 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
WO2001007038A3 (en) Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy
WO1999052518A3 (en) New treatments for nervous disorders
AU2462097A (en) The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
IL149669A0 (en) NEW THERAPEUTIC COMBINATIONS OF (S) -2-(BENZYLAMINO-METHYL)-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e] INDOL-8-ONE AND NEUROLEPTICS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
WO2001045688A3 (en) Use od desloratadine for treating allergic and inflammatory conditions in pediatric patients
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
IL130666A0 (en) Active derivatives of valproic acid for the treatment of neurological and psychotic disorders and a method for their preparation
AU2517499A (en) Use of diphenylmethylene piperidine derivatives in the manufacture of a medicament for the treatment of movement disorders

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: ALCON MANUFACTURING LTD.

Free format text: FORMER OWNER(S): ALCON LABORATORIES, INC

Owner name: KYOWA HAKKO KOGYO CO. LTD.

Free format text: FORMER OWNER(S): ALCON LABORATORIES, INC

PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170615